Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.31 (
AMP-activated protein kinase
)
13,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Medullary thyroid cancer
(
MTC
) is associated with activation of mammalian target of rapamycin (mTOR) signaling pathways. Recent studies showed that the antidiabetic agent metformin decreases proliferation of cancer cells through 5'-AMP-activated protein kinase (
AMPK
)-dependent inhibition of mTOR. In the current study, we assessed the effect of metformin on
MTC
cells. For this purpose, we determined growth, viability, migration, and resistance to anoikis assays using two
MTC
-derived cell lines (TT and MZ-CRC-1). Expressions of molecular targets of metformin were examined in
MTC
cell lines and in 14 human
MTC
tissue samples. We found that metformin inhibited growth and decreased expression of cyclin D1 in
MTC
cells. Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells. Metformin had no significant effects on pAKT in the cell lines examined. Metformin-inducible
AMPK
activation was noted only in TT cells. Treatment with
AMPK
inhibitor (compound C) or
AMPK
silencing did not prevent growth inhibitory effects of metformin in TT cells. Metformin had no effect on
MTC
cell migration but reduced the ability of cells to form multicellular spheroids in nonadherent conditions. Immunostaining of human
MTC
showed over-expression of cyclin D1 in all tumors compared with corresponding normal tissue. Activation of mTOR/p70S6K was detected in 8/14 (57.1%) examined tumors. Together, these findings indicate that growth inhibitory effects in
MTC
cells are associated with downregulation of both mTOR/6SK and pERK signaling pathways. Expression of metformin's molecular targets in human
MTC
cells suggests its potential utility for the treatment of
MTC
in patients.
...
PMID:Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. 2238 81